Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2005-03-22 (21 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: SAINTE-FOY-LA-GRANDE (33220), Gironde
PHARMACIE DES HALLES : revenue, balance sheet and financial ratios
PHARMACIE DES HALLES is a French company
founded 21 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINTE-FOY-LA-GRANDE (33220),
this company of category PME
shows in 2023 a revenue of 4.9 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DES HALLES (SIREN 482031481)
Indicator
2024
2023
2022
2020
2019
2018
2017
Revenue
N/C
4 928 635 €
4 609 045 €
2 298 135 €
2 444 812 €
2 562 124 €
3 501 322 €
Net income
367 692 €
344 760 €
376 197 €
249 894 €
254 162 €
227 650 €
268 738 €
EBITDA
N/C
508 194 €
550 527 €
334 788 €
329 945 €
319 107 €
440 186 €
Net margin
N/C
7.0%
8.2%
10.9%
10.4%
8.9%
7.7%
Revenue and income statement
In 2024, PHARMACIE DES HALLES generates positive net income of 368 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 269 k€ -> 368 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
367 692 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 26%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 68%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
25.925%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
68.111%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DES HALLES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2022
2023
2024
Debt ratio
0.087
23.88
22.248
21.968
42.589
32.739
25.925
Financial autonomy
88.826
70.425
72.627
74.063
61.071
64.258
68.111
Repayment capacity
0.008
1.806
1.563
1.68
3.109
2.731
None
Cash flow / Revenue
7.486%
8.671%
10.386%
10.412%
8.966%
7.927%
None%
Sector positioning
Debt ratio
25.932024
2022
2023
2024
Q1: 16.46
Med: 58.48
Q3: 154.77
Good
In 2024, the debt ratio of PHARMACIE DES HALLES (25.93) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
68.11%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good+5 pts over 3 years
In 2024, the financial autonomy of PHARMACIE DES HALLES (68.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
2.73 years2023
2022
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of PHARMACIE DES HALLES (2.73) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 216.84. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
216.839
Liquidity indicators evolution PHARMACIE DES HALLES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2022
2023
2024
Liquidity ratio
397.366
250.092
306.1
359.972
228.648
214.348
216.839
Interest coverage
1.12
0.011
0.013
0.016
1.317
0.926
None
Sector positioning
Liquidity ratio
216.842024
2022
2023
2024
Q1: 129.46
Med: 182.14
Q3: 260.79
Good
In 2024, the liquidity ratio of PHARMACIE DES HALLES (216.84) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.93x2023
2022
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE DES HALLES (0.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 170 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 801 days. Excellent situation: suppliers finance 631 days of the operating cycle (retail model).
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
170 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
801 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DES HALLES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2022
2023
2024
Operating WCR
113 933 €
240 122 €
241 034 €
258 494 €
498 053 €
615 242 €
0 €
Inventory turnover (days)
12
26
32
34
42
42
0
Customer payment term (days)
4
7
5
5
11
9
170
Supplier payment term (days)
34
45
44
42
35
49
801
Positioning of PHARMACIE DES HALLES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE DES HALLES is estimated at
5 133 252 €
(range 3 574 715€ - 7 679 638€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
3574k€5133k€7679k€
5 133 252 €Range: 3 574 715€ - 7 679 638€
NAF 5 année 2024
Valuation method used
Net Income Multiple
367 692 €
×
14.0x
=5 133 252 €
Range: 3 574 716€ - 7 679 639€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DES HALLES with other companies in the same sector:
Frequently asked questions about PHARMACIE DES HALLES
What is the revenue of PHARMACIE DES HALLES ?
The revenue of PHARMACIE DES HALLES in 2023 is 4.9 M€.
Is PHARMACIE DES HALLES profitable?
Yes, PHARMACIE DES HALLES generated a net profit of 368 k€ in 2024.
Where is the headquarters of PHARMACIE DES HALLES ?
The headquarters of PHARMACIE DES HALLES is located in SAINTE-FOY-LA-GRANDE (33220), in the department Gironde.
Where to find the tax return of PHARMACIE DES HALLES ?
The tax return of PHARMACIE DES HALLES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DES HALLES operate?
PHARMACIE DES HALLES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart